This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial

This study has been completed.
Sponsor:
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT00056563
First received: March 18, 2003
Last updated: April 24, 2014
Last verified: April 2014
History of Changes
Results First Received: May 20, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Parkinson's Disease
Interventions: Device: Bilateral Deep Brain Stimulation
Other: best medical therapy

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patient recruitment begun in May 2002 and the discontinuation of randomization to the BMT arm was approved in August 2005 and participating sites received their IRB approval of this change through October 2005. A total of 255 patients were randomized to either BMT or DBS from 7 VA medical centers and 6 affiliated university sites.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
An additional 23 patients were screened after signing the informed consent form but not randomized. 11 of them weren’t willing to participate in the follow-up visits after intervention, 7 of them had neuropsychological dysfunction, 2 of them were not responsive to levodopa, and 3 had medical contraindication to surgery and/or DBS stimulation.

Reporting Groups
  Description
1: Bilateral Deep Brain Stimulation

Bilateral Deep Brain Stimulation

Bilateral Deep Brain Stimulation : The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
2: Best Medical Therapy

Best Medical Therapy

best medical therapy : Participants will initially be randomized to DBS or to 6 months of

Participant Flow:   Overall Study
    1: Bilateral Deep Brain Stimulation   2: Best Medical Therapy
STARTED   121   134 
COMPLETED   121   134 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
1: Bilateral Deep Brain Stimulation

Bilateral Deep Brain Stimulation

Bilateral Deep Brain Stimulation : The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
2: Best Medical Therapy

Best Medical Therapy

best medical therapy : Participants will initially be randomized to DBS or to 6 months of "best medical therapy." BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months.
Total Total of all reporting groups

Baseline Measures
   1: Bilateral Deep Brain Stimulation   2: Best Medical Therapy   Total 
Overall Participants Analyzed 
[Units: Participants]
 		 121   134   255 
Age 
[Units: Participants]
 		     
<=18 years   0   0   0 
Between 18 and 65 years   90   97   187 
>=65 years   31   37   68 
Age 
[Units: Years]
Mean (Standard Deviation) 		 62.4  (8.8)   62.3  (9.0)   62.3  (8.9) 
Gender 
[Units: Participants]
 		     
Female   23   24   47 
Male   98   110   208 
Region of Enrollment 
[Units: Participants]
 		     
United States   121   134   255 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Difference of Time Spent in the 'on' State Without Troublesome Dyskinesia Based on Patient Motor Diaries as Compared to the Baseline.   [ Time Frame: at six months ]
  Show Outcome Measure 1

2.  Secondary:   The Change of Scores on the UPDRS for Blinded Assessed Motor Function 'Off' Medication and 'on' Stimulation   [ Time Frame: at six months ]
  Show Outcome Measure 2


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
A limitation of this study is that the STN and GPi cases are pooled into a single DBS group. When the study was planned, it was thought that differences between STN and GPi at six months would be small, which was tested during the study analysis.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Frances M. Weaver, Ph.D, Study Investigator
Organization: Center for Management of Complex Chronic Care
phone: (708) 202-2414
e-mail: Frances.Weaver@va.gov


Publications of Results:
Weaver FM, Rothlind J, Stern M. Deep Brain Stimulation for Patients with Advanced Parkinson Disease Reply. [Letter to the Editor]. JAMA : the journal of the American Medical Association. 2009 May 20; 301(19):1985.
Follett K, Weaver FM, Stern M. Comment: Deep-brain stimulation for Parkinson's Disease. The New England journal of medicine. 2010 Sep 3; 363(10):988.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):


Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00056563     History of Changes
Obsolete Identifiers: NCT00101556
Other Study ID Numbers: 468 Phase I
Study First Received: March 18, 2003
Results First Received: May 20, 2013
Last Updated: April 24, 2014